Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use
disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia. The company trades on NASDAQ exchange. The company headquarter is located in Charlottesville, VA. The company was established in the 2010.
| Ticker | ADIL |
| Long Name | Adial Pharmaceuticals, Inc. |
| Short Name | Adial Pharmaceuticals |